Orthopaedic researchers at UCLA have published the largest literature sweep yet performed on the six peptides that dominate the recovery and performance market. The paper — a scoping review out of the Department of Orthopaedic Surgery at the David Geffen School of Medicine — went online ahead of print in the American Journal of Sports Medicine on August 11, 2026, and reached general press in early September under the line that gave the coverage its headline: with peptide supplements, marketing outpaces the medicine.
The six compounds examined are BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. That is close to a complete list of what the research-peptide channel sells for tissue repair and recovery, which is what makes the paper worth reading in full rather than from the press summary — particularly because the summaries have dropped the single most important qualifier in the methods section.
Research-context information only. This article reports on a published peer-reviewed scoping review and press coverage of it. It is not medical advice, and nothing here is a recommendation to use, dose or discontinue any compound. The six compounds discussed are sold as research-use-only material, are not approved by the FDA for human use, and have not been evaluated for safety, purity or potency as sold in that channel. The review's own conclusion is that these compounds should not be treated as a substitute for or addition to established orthopaedic care. Consult a licensed physician for personal medical decisions.
What the review did
The design is a scoping review, not a meta-analysis — an important distinction, because a scoping review maps what literature exists and how good it is, rather than pooling results into a single effect size.
Three independent reviewers searched PubMed under PRISMA reporting guidelines, running permutations of each peptide name against musculoskeletal tissue terms. Two reviewers screened each paper, with a third acting as tiebreaker. UCLA's newsroom account puts the number of studies examined at 565.
| Element | Detail |
|---|---|
| Design | Scoping review, PRISMA-guided |
| Database | PubMed |
| Compounds | BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, GHK-Cu |
| Tissue terms | bone, fracture, muscle, tendon, ligament, meniscus, cartilage |
| Screening | 3 independent reviewers, 2-reviewer screen with tiebreaker |
| Studies examined | 565 (per UCLA newsroom) |
| Preclinical share | 67% of identified publications used animal models |
Three findings carry the paper. First, 67% of identified publications used preclinical animal models — most commonly rats. Second, in those animal models each compound showed distinct mechanisms and "promising but variable" effects on tendon, muscle, bone and ligament healing. Third, human clinical studies were "limited to a handful of investigations, most lacking robust controls or rigorous study designs," with heterogeneous data showing modest improvements at best, and those confined to metabolic bone health and degenerative knee pain.
The authors also note that dosing and route of administration varied substantially across the literature they found — which is its own finding, and one that anyone comparing published protocols to vendor-channel figures will recognise.
The qualifier the coverage dropped
The review is scoped to musculoskeletal outcomes. That is not an incidental detail — it is built into the search strategy, which paired every peptide term with bone, fracture, muscle, tendon, ligament, meniscus or cartilage.
The consequence is that large bodies of literature on these same six compounds were never in the search frame:
- GHK-Cu has its most developed evidence base in dermatology and cosmetic science, where it has been studied as a topical for decades. A musculoskeletal tissue search does not retrieve it. The review's lead author made a related point in press interviews, describing a pattern where a topical agent with limited clinical evidence for a skin condition gets reframed as an injectable for musculoskeletal problems — which is a criticism of the marketing leap, not a verdict on the dermatology literature itself.
- BPC-157 originates in gastrointestinal research, and the bulk of its published animal work concerns gut and vascular models rather than tendon.
- CJC-1295 and ipamorelin are growth-hormone secretagogues whose human studies typically report endocrine endpoints — GH pulse amplitude, IGF-1 concentration — not healing rates. Those papers sit outside a tissue-term search almost entirely.
So the accurate reading of the conclusion is specific: for musculoskeletal recovery and athletic performance, the human evidence is thin to absent. That is a real and well-supported finding about the exact claims this market makes loudest. It is not a finding that the compounds have been broadly tested and failed, and the review does not assert that.
Both halves of that matter. The coverage that flattened this into "peptides don't work" overstated it; the response that dismisses the paper because it missed the dermatology literature misses that the paper was never looking there and still lands squarely on the claims most vendors actually advertise.
What this changes in practice
Very little changes mechanically, and the honest summary is that the review formalises something the better-informed end of this market already assumed.
On the strength of the claims. Anyone who has read the primary literature on these compounds will not be surprised by a 67% preclinical share — that ratio has been visible for years. What the review adds is a defensible citation for it. Our own BPC-157 benefits and TB-500 benefits articles have described this evidence base as predominantly rodent-model work throughout, and this paper is now the cleanest single source for that characterisation.
On regulatory trajectory. A high-profile evidence review in a major sports medicine journal is the kind of document that gets cited in rulemaking. The FDA's compounding track spent 2026 working through which peptides may be prepared against a prescription, and BPC-157 was already among the more contested entries on that docket. A published finding of absent human efficacy data could be cited in that debate. Our summary of where peptide legality stands in the US tracks how the compounding and research-supply questions move separately.
On dosing figures. The authors' note about heterogeneous dosing and routes across the literature is worth sitting with. Protocols circulating in the research channel are frequently presented as though derived from trials; the review's finding is that the underlying studies do not converge on a consistent regimen even among themselves.
On the compounds with approved counterparts. Nothing in this review changes supply. It is a literature paper, not an enforcement action — distinct from the five FDA warning letters posted on September 1, which did affect what specific sellers list.
